Advertisements

Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus

Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus.....»»

Category: press-releasesSource: businesswireindiaJun 14th, 2017

Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting

Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting.....»»

Category: press-releasesSource: businesswireindiaOct 20th, 2017

Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG

Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG.....»»

Category: press-releasesSource: businesswireindiaOct 18th, 2016

Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS

Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS.....»»

Category: press-releasesSource: businesswireindiaSep 17th, 2016

Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation

Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation.....»»

Category: press-releasesSource: businesswireindiaJun 7th, 2017

European regulator EMA to review Biocon-Mylan’s version of insulin glargine

European regulator EMA to review Biocon-Mylan’s version of insulin glargine.....»»

Category: featuresSource: livemintNov 3rd, 2016

Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal Phase 2 ALTA Trialat 18th World Conference on Lung Cancer

Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal Phase 2 ALTA Trialat 18th World Conference on Lung Cancer.....»»

Category: press-releasesSource: businesswireindiaSep 28th, 2017

Publication of Clinical Data Demonstrating Low Immunogenicity and Excellent Efficacy of Nuwiq® in Previously Untreated Patients

Publication of Clinical Data Demonstrating Low Immunogenicity and Excellent Efficacy of Nuwiq® in Previously Untreated Patients.....»»

Category: press-releasesSource: businesswireindiaAug 23rd, 2017

Glenmark’s dermatitis molecule displays positive results in phase-2a trial

Glenmark’s dermatitis molecule displays positive results in phase-2a trial.....»»

Category: featuresSource: livemintAug 1st, 2017

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting.....»»

Category: press-releasesSource: businesswireindiaJun 24th, 2017

Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy

Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy.....»»

Category: press-releasesSource: businesswireindiaMar 5th, 2017

ABOUND Data Presented at the World Conference on Lung Cancer Further Explores Safety and Efficacy of ABRAXANE® for Challenging Patient Populations

ABOUND Data Presented at the World Conference on Lung Cancer Further Explores Safety and Efficacy of ABRAXANE® for Challenging Patient Populations.....»»

Category: press-releasesSource: businesswireindiaDec 6th, 2016

Updated Phase III Results Reinforce Safety and Efficacy of Praxbind® (idarucizumab) in Urgent Situations

Updated Phase III Results Reinforce Safety and Efficacy of Praxbind® (idarucizumab) in Urgent Situations.....»»

Category: press-releasesSource: businesswireindiaNov 16th, 2016

Data on Early Onset of Efficacy for Oral OTEZLA® (apremilast) in Active Psoriatic Arthritis Presented at American College of Rheumatology

Data on Early Onset of Efficacy for Oral OTEZLA® (apremilast) in Active Psoriatic Arthritis Presented at American College of Rheumatology.....»»

Category: press-releasesSource: businesswireindiaNov 14th, 2016

Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study

Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study.....»»

Category: press-releasesSource: businesswireindiaOct 27th, 2016

J P Nadda assures support for treatment of fire-hit patients

J P Nadda assures support for treatment of fire-hit patients.....»»

Category: economySource: business-standardOct 19th, 2016

Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016

Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016.....»»

Category: press-releasesSource: businesswireindiaOct 10th, 2016

New long-term data demonstrates continued safety and beneficial effect of OFEV® (nintedanib) for patients with IPF

New long-term data demonstrates continued safety and beneficial effect of OFEV® (nintedanib) for patients with IPF.....»»

Category: press-releasesSource: businesswireindiaSep 8th, 2016

ESC Congress 2016 Late Breaking Science RegistryLatest data on dabigatran etexilate safety and effectiveness profile show low rates of bleeding and stroke in NVAF patients in routine clinical care

ESC Congress 2016 Late Breaking Science RegistryLatest data on dabigatran etexilate safety and effectiveness profile show low rates of bleeding and stroke in NVAF patients in routine clinical care.....»»

Category: press-releasesSource: businesswireindiaAug 30th, 2016

Biocon, Quark to start clinical tests for eye disorder drug

Biocon, Quark to start clinical tests for eye disorder drug.....»»

Category: featuresSource: livemintJun 23rd, 2016

TAGRISSO (OSIMERTINIB) SHOWS CLINICAL ACTIVITY IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM LUNG CANCER

TAGRISSO (OSIMERTINIB) SHOWS CLINICAL ACTIVITY IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM LUNG CANCER.....»»

Category: press-releasesSource: businesswireindiaJun 7th, 2016